{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-010104","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.947236+00:00","generated_at":"2026-05-31T11:54:04.558670+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Dermata Therapeutics reports Q2 2024 results; DMT310 Phase 3 trial enrollment over 50%","bullets":["Net cash $4.9M at June 30, 2024, down from $7.4M at Dec 31, 2023; expects to fund ops into Q4 2024.","Raised $2.3M in net proceeds from May 2024 warrant inducement financing.","R&D expenses $2.0M in Q2 2024 vs. $0.8M in Q2 2023 due to STAR-1 trial costs.","DMT310 Phase 3 STAR-1 trial enrolled over 50% of patients; topline data expected Q1 2025.","DMT410 partnership discussions ongoing for topical botulinum toxin delivery."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-010104","json":"https://secwatch.observer/filing/0001654954-24-010104.json","markdown":"https://secwatch.observer/filing/0001654954-24-010104.md","text":"https://secwatch.observer/filing/0001654954-24-010104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424010104/0001654954-24-010104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424010104/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:54:04.558670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}